GVHD
GVHD
Advertisement
Cecilia BrownGVHD | November 29, 2023
The findings show the importance of assessing the histologic grade of gastrointestinal GVHD.
Read More
Cecilia BrownGVHD | November 29, 2023
No other trials have tested nonpharmacological interventions to improve quality of life in patients with cutaneous GVHD.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | November 27, 2023
Oncology nurses must understand these diverse manifestations and their potential impact on patients’ daily lives. 
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | November 27, 2023
Nearly 1 of 5 patients (18%) with cGVHD had kidney dysfunction, with 8% having moderate-severe dysfunction.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | November 9, 2023
As a trusted profession, oncology nurses are critical in helping women manage genital cGVHD.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | November 9, 2023
Oncology nurses are in a pivotal position to assess for symptoms of female genital cGVHD and to intervene early.
Cecilia BrownGVHD | October 31, 2023
Researchers suggest considering multiple factors when seeking a donor for a patient.
Cecilia BrownGVHD | October 30, 2023
All patients were adults with a history of allogeneic HSCT diagnosed with chronic, extensive GVHD.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | October 13, 2023
Understanding how patients and caregivers describe their health status is crucial to knowing what matters most to patients.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | October 13, 2023
Different types of secondary solid tumors can occur after allogeneic HSCT, including oral cancer.
Cancer Nursing Today EditorsGVHD | October 13, 2023
The frequency of veno-occlusive disease, hyperacute and acute GVHD, and chronic GVHD were not different between groups.
Cancer Nursing Today EditorsGVHD | October 13, 2023
Researchers evaluated two categories of immunosuppressive therapy to evaluate the best approach.
Dustin SamplesConferences | September 13, 2023
It is important to monitor patients who have elevated CMV levels to detect infection and progression early.
Dustin SamplesConferences | September 13, 2023
Results from this meta-review suggest that more prophylactic strategies are needed in the fight against GVHD.
Dustin SamplesConferences | September 13, 2023
Intensive salvage therapy had a 54% complete remission rate whereas non-intensive salvage therapy was lower at 18%.
Dustin SamplesConferences | September 8, 2023
The study used only single-agent tacrolimus for GVHD prophylaxis.
Dustin SamplesConferences | September 8, 2023
Non-relapse mortality was low, and there was good GVHD control with the prophylaxis.
Dustin SamplesConferences | September 8, 2023
Results were further improved when Orca-T was given in combination with a regimen of busulfan, fludarabine, and thiotepa.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | September 7, 2023
There are 5 criteria that you should discuss with your patients if you suspect frailty.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | September 7, 2023
Exercise, diet, and stress reduction can go a long way to improve patient frailty.
Advertisement
Advertisement
Advertisement